Frontiers | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | Oncology
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
In vitro validation of EDIT-101 a, Schematic representation of... | Download Scientific Diagram
Editas' CRISPR asset make strides after positive eye disease trial
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges - ScienceDirect
Allergan and Editas Medicine Announce Dosing of First
Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials | British Journal of Ophthalmology
Editas Medicine Stock | EDIT-101 Data SOON - Here's What to Expect! - YouTube
Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy "Signals" in Two Patients
News: CRISPR clinical trials overview 2020 - CRISPR Medicine
Research and Pipeline | Editas Medicine
Gene Editing
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
Editas Medicine (@editasmed) / Twitter
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10 | Editas Medicine
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 | Nature Medicine
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research: Molecular Therapy - Methods & Clinical Development
Frontiers | Prime Editing for Inherited Retinal Diseases | Genome Editing
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy - ScienceDirect
Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
Clinical Data from Editas Medicine's Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the
JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022 | Fierce Biotech
Editas and Allergan Make Gene-Editing History With First Treatment of Blindness Drug | The Motley Fool
Yuancheng (Ryan) Lu on Twitter: "Editas has their gene editing AAV therapy application approved by FDA. Will start clinical trials. https://t.co/gD60RtSM6E" / Twitter
Gene Therapy for LCA10: The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) Update
Editas Wins FDA Approval for IND of CRISPR Treatment for LCA10
Editas Medicine Announces Enrollment of the First Pediatric
